[Point-of-care testing for D-dimer in the exclusion of venous thromboembolism: a critical analysis].

François Grand, Florence Blanc-Jouvan, Céline Delassasseigne, Hubert Galinat, Pierre-Marie Roy, Laurie Talon, Marie Toussaint-Hacquard, Laurent Macchi
{"title":"[Point-of-care testing for D-dimer in the exclusion of venous thromboembolism: a critical analysis].","authors":"François Grand, Florence Blanc-Jouvan, Céline Delassasseigne, Hubert Galinat, Pierre-Marie Roy, Laurie Talon, Marie Toussaint-Hacquard, Laurent Macchi","doi":"10.1684/abc.2023.1839","DOIUrl":null,"url":null,"abstract":"<p><p>Point-of-care testing (POCT) for D-dimer is an alternative to -laboratory testing for the exclusion of venous thromboembolism (VTE). This critical review by the \"CEC et biologie délocalisée\" working group of the \"Société Française de Thrombose et d'Hémostase\" (French Society of -Thrombosis and Haemostasis) aims to present the characteristics of six POCT D-dimer assays available in France in 2023. The article highlights the need to define VTE -exclusion thresholds specific to each technique and validated by clinical studies. There is insufficient data to validate the use of cut off suggested by manufacturers, and age-adjusted thresholds. The article discusses the role of laboratories in justifying and prescribing POCT D-dimer, according to objective criteria, such as the availability and turnaround time of classical laboratory tests. They should also encourage rational prescribing, limited to patients with low risk of venous thromboembolism, following an assessment of clinical probability according to national and international guidelines.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1684/abc.2023.1839","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Point-of-care testing (POCT) for D-dimer is an alternative to -laboratory testing for the exclusion of venous thromboembolism (VTE). This critical review by the "CEC et biologie délocalisée" working group of the "Société Française de Thrombose et d'Hémostase" (French Society of -Thrombosis and Haemostasis) aims to present the characteristics of six POCT D-dimer assays available in France in 2023. The article highlights the need to define VTE -exclusion thresholds specific to each technique and validated by clinical studies. There is insufficient data to validate the use of cut off suggested by manufacturers, and age-adjusted thresholds. The article discusses the role of laboratories in justifying and prescribing POCT D-dimer, according to objective criteria, such as the availability and turnaround time of classical laboratory tests. They should also encourage rational prescribing, limited to patients with low risk of venous thromboembolism, following an assessment of clinical probability according to national and international guidelines.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[d -二聚体在排除静脉血栓栓塞中的即时检测:一项关键分析]。
d -二聚体的即时检测(POCT)是实验室检测排除静脉血栓栓塞(VTE)的替代方法。法国血栓和止血学会的“CEC et biologie dsamlocalissame”工作组的这篇重要综述旨在介绍2023年法国可用的六种POCT d -二聚体测定方法的特点。这篇文章强调了确定静脉血栓栓塞排除阈值的必要性,具体到每一种技术,并通过临床研究验证。没有足够的数据来验证制造商建议的截断和年龄调整阈值的使用。本文根据客观标准,如经典实验室测试的可用性和周转时间,讨论了实验室在证明和处方POCT d -二聚体方面的作用。他们还应鼓励合理的处方,仅限于静脉血栓栓塞风险低的患者,并根据国家和国际指南对临床可能性进行评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Complementarity between Bayesian Internal Quality Control results management and External Quality Assessment bivariate z-score analysis: application to a concrete case study. [Can TDABC (Time-Driven Activity-Based Costing) help the NOVO hospital's medical biology laboratory to value the appropriate prescription? - Role of the biologist in reducing healthcare costs]. [Clinical associations of anti-Jo1 antibodies in a Moroccan population]. [Clinical-biological approaches to the spectrophotometric detection of oxyhemoglobin and bilirubin in CSF in the management of aneurysmal subarachnoid hemorrhage]. [Evaluation of the CellaVision® DM-1200 system for detecting and quantifying schistocytes].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1